Old World monkeys could be key to a new, powerful rheumatoid arthritis therapy

November 16, 2017, University of Southern California
RTD-1 ribbon model. Credit: Keck School of Medicine of USC

In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa. It was a particular peptide only found in Old World monkeys, called θ-defensin 1 (RTD-1), that the researchers believed had the potential to stop—or even reverse—the progression of rheumatoid arthritis, an autoimmune disease that affects about 1.5 million people in the United States. The promising results of their study were published today in PLOS ONE.

"RTD-1 is the prototype of a family of small cyclic peptides (θ-defensins), the only circular proteins in the animal kingdom," says study author Michael Selsted, MD, PhD, chair and professor of pathology at the Keck School. "Previous studies have shown that RTD-1 modulates lethal inflammation in animal models of infection, and we predicted that RTD-1's protective mechanism in those models would translate to rheumatoid arthritis, a in which chronic inflammation produces irreversible joint damage."

To test their hypothesis, the researchers administered RTD-1 to rats with arthritis for 11 days and observed whether the treatment had any anti-arthritic effects. Within 24 hours of the first administered dose, RTD-1 had significantly reduced arthritis progression. At the end of the treatment, rats that received RTD-1 also had markedly lower arthritis severity scores as compared with rats that had not received RTD-1.

Next, RTD-1 was tested in rats with severe arthritis. The research team found that RTD-1 produced a rapid reduction in arthritis severity within 48 hours of treatment, with complete resolution of clinical disease in all treated rats by day 15.

RTD-1 was then compared to two gold standard treatments for rheumatoid arthritis—methotrexate and etanercept—in with severe arthritis. The team found that RTD-1 treatment resulted in greater disease resolution than methotrexate or etanercept. RTD-1 also achieved the highest rate of complete disease resolution of the three treatments.

"Since most available rheumatoid therapies achieve mild to moderate improvements, and disease remission is rare, there's a continuing search for new therapeutics," Selsted says. "Our findings strongly suggest that RTD-1 has potential as a completely new agent for treating . RTD-1-like molecules may also be effective in the of other inflammatory diseases and cancer."

Explore further: Rheumatoid arthritis linked to an increased risk of COPD

More information: PLOS ONE (2017). journals.plos.org/plosone/arti … journal.pone.0187868

Related Stories

Rheumatoid arthritis linked to an increased risk of COPD

October 19, 2017
New research suggests that rheumatoid arthritis may increase the risk of developing chronic obstructive pulmonary disease (COPD). The findings, which appear in Arthritis Care & Research, indicate that greater vigilance may ...

Obesity may influence rheumatoid arthritis blood tests

April 10, 2017
New research reveals that in women, obesity may influence blood tests used to diagnose and monitor rheumatoid arthritis. The findings, which appear in Arthritis Care & Research, indicate that physicians need to take obesity ...

New oral treatment option for rheumatoid arthritis

June 19, 2017
Patients suffering from rheumatoid arthritis are treated for around six months with the standard anti-rheumatic agent methotrexate, to which many patients respond very well. However, if they do not respond and no remission ...

Scientists discover new mechanism that leads to inflammation in rheumatoid arthritis

March 2, 2017
New research findings published in the Journal of Leukocyte Biology, suggest that synovial CD4+ T cells that produce IL-21 contribute to joint inflammation by activating synovial fibroblasts in rheumatoid arthritis patients. ...

Study examines opioid use in patients with rheumatoid arthritis

June 21, 2017
A new analysis indicates that the use of opioid pain medications in older US rheumatoid arthritis patients peaked in 2010 and is now declining slightly. By 2014, 41% of rheumatoid arthritis patients were regular opioid users.

Pedometers increase activity and decrease fatigue in rheumatoid arthritis patients

April 5, 2017
Providing pedometers, with and without providing step targets, to individuals with rheumatoid arthritis increased activity levels and decreased fatigue in a recent study.

Recommended for you

How environmental pollutants and genetics work together in rheumatoid arthritis

April 19, 2018
It has been known for more than three decades that individuals with a particular version of a gene—human leukocyte antigen (HLA)—have an increased risk for rheumatoid arthritis.

The bugs in your gut could make you weak in the knees

April 19, 2018
Bacteria in the gut, known as the gut microbiome, could be the culprit behind arthritis and joint pain that plagues people who are obese, according to a new study published today in JCI Insight.

Researchers identify peptide produced during cartilage deterioration as a potential source of osteoarthritis pain

April 11, 2018
Osteoarthritis is one of the most common causes of chronic pain in the world. More than 30 million people in the United States alone suffer from osteoarthritis, or OA, which can affect any moveable joint of the body, including ...

Flare-responsive hydrogel developed to treat arthritis

April 3, 2018
Arthritis flares - the unpredictable and often sudden worsening of arthritis symptoms—can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic ...

Drug compound shows promise against rheumatoid arthritis

March 28, 2018
Scientists have designed a new drug compound that dials down inflammation, suggesting possible future uses against autoimmune disorders such as rheumatoid arthritis.

Chromosomal loop signatures could identify poor drug response in arthritis

March 28, 2018
Chromosomal loop signatures found in blood samples obtained in early rheumatoid arthritis could identify patients that will not respond adequately to 'anchor' treatment drug methotrexate.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.